The company has a product for blood biomarker testing. The product is ready for the market in 2019. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark.
Qlife Holding AB aims to simplify the market evaluation of the company through clear information. If you’re interested in the coming IPO offering, there is a possibility to make a registration. The preliminary start of the subscription period is January, 2020.
The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.
If you’re interested in the coming IPO offering, please sign up your name and e-mail address below. You will receive an offering to subscribe when the subscription period is initiated, preliminarily in January, 2020.
In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions.
CEO Thomas Warthoe will present Qlife at Stora Aktiedagen (Shareholder’s Day) in Gothenburg on 4 November and in Stockholm on 25 November.
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier.
Qlife is showcased by the Danish Minister of Health and the Minister for Industry, Business and Financial Affairs for the launch of new public program for innovative purchasing of medical equipment
In the enclosed Newsletter you will find updated information about our operations and preparations for the next steps.
Biomarkers in our blood can show us a lot about our health, the development of a disease or how tough we have been to our body during a workout.
Every day, the Danish healthcare system produces a large amount of data.
Six interesting companies in total will present their businesses.